Clinical trial NCT05698602: Safety and Performance of NivolisMonitor and NivolisAnton for Monitoring Patients on Ventilatory Assistance at Home
Official title: Evaluation of the Safety and Clinical Performance of NivolisMonitor and NivolisAnton: Medical Devices for Monitoring Patients Treated With Home Ventilatory Assistance Devices
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Respiratory Insufficiency
Respiratory Failure
Home Monitoring
Keywords: Noninvasive ventilation
Nasal High Flow
Home Monitoring
Transcutaneous CO2 pressure
Lead sponsor: VIVARDIS
Sponsor class: INDUSTRY
First posted: 2023-01-26
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: NivolisMonitor and NivolisAnton are new devices developed by Vivardis. NivolisMonitor is a generic and autonomous device for remote monitoring of ventilatory parameters generated by ventilatory assistance systems. NivolisMonitor uses its sensors to measure ventilation parameters such as pressure, flow, temperature and relative humidity, Fi02 provided by respiratory treatment devices (NIV, HDN (High Nasal Flow) and Oxygen therapy). NivolisMonitor records this data, stores it and transmits it to the healthcare professionals in charge of the patient. NivolisAnton is a medical device for telemonitoring of transcutaneous capnia, it thus helps to make recordings at the patient's home and to transmit data to healthcare professionals.

The main objective of this study is to show that the use of NivolisMonitor and NivolisAnton is done in complete safety and that the clinical performances of these two devices are achieved. For this, the data measured by NivolisMonitor will be compared with the data provided by the treatment devices used by patients at home and the data provided by NivolisAnton will be compared with the data reported by the transcutaneous capnia monitor.

The secondary objectives concern the evaluation of the acceptability/usability of the devices by patients and healthcare professionals.

This evaluation will take the form of an observational clinical study on 10 patients, including :

* a selection of patients already treated with NIV or HDN according to the inclusion/non-inclusion criteria and submission of the information note
* an inclusion visit taking place during a routine pulmonological follow-up visit for these patients with collection of the free and informed consent of each patient. The blood gas data collected during this routine consultation will be compiled in the study observation book.
* a 3-day monitoring period:

  * use over 3 days of the NivolisMonitor device at home, with on the last day the completion of the patient acceptability/usability questionnaire
  * overnight use of NivolisAnton
* a teleconsultation to close the study for each patient
* completion of the healthcare professional acceptability/usability questionnaire at the end of the study

Detailed description: Rationale :

Since the early 2000s, there has been growing interest in remote monitoring and telemonitoring of patients with chronic respiratory pathologies, in particular patients treated with Non-Invasive Ventilation (NIV). Thus, many studies have focused on the benefits of remote monitoring or telemonitoring. Although the concept of remote home ventilation monitoring seems intuitively useful, analysis of the literature indicates a need for trials with solid evidence. In the same way, nocturnal recording of transcutaneous capnia has shown its reliability and its interest for the follow-up of patients under respiratory assistance at home.

NivolisMonitor and NivolisAnton are new devices developed by Vivardis.

Study Design :

10 patients must be included in this one arm interventional study.

Nivolis study consists in :

* a pre-inclusion visit : V0
* an inclusion visit : V1
* the 3-days study period
* a end of study visit : V2

Pre-inclusion visit V0 :

The patients included in this study are patients already treated with a Home Ventilatory Assistance (NIV) or Home Nasal High Flow device (HDN). Their care is provided by a Home Health Provider (HHP).

Pre-inclusion of patients is carried out by the investigating pulmonologist and the HHP, it aims to:

1. Check the inclusion and non-inclusion criteria
2. And if the patient is eligible, inform the patient of the study, provide him with the information note and the form for obtaining his free and informed consent.

After having been informed, the patients have a period of reflection (1 week) before the inclusion visit during which the pulmonologist will collect the free, informed and written consent of the participant.

Inclusion Visit V1 :

This visit is a classic pulmonological consultation for the follow-up of a patient with Chronic Respiratory Failure by a pulmonologist.

This visit will take place as follows:

1. Collection of the patient's free and informed consent. A copy of the information note and the signed consent is given to the participant. The original copy is kept by the investigating doctor, a third copy is kept by the sponsor.
2. The patient will benefit from his usual consultation by the pulmonologist
3. NIV or HDN device settings: NIV or HDN settings

Data collected:

* Arterial gasometry
* NIV Settings
* HDN settings
* Oxygen therapy

  3-days study period : For each patient enrolled in the study, at home, a NivolisMonitor recording for 3 days and a NivolisAnton recording for one night are performed.

The installation of NivolisMonitor and NivolisAnton is carried out by the Home Health Provider who supports the patient as part of the provision of his Ventilatory Assistance or Nasal High Flow device.

End of Study Visit V2 :

This visit is a pneumological teleconsultation for the follow-up of a patient with Respiratory sufficiency Chronic by a pulmonologist.

Data collected during this visit :

* NIV settings and usage
* HDN settings
* Sentec SDM Monitor data
* NivolisMonitor data
* NivolisAnton data
* Usability/Acceptability:

Data Management :

All data concerning visits V0, V 1, V2 will be entered into a CRF. Neither the CRF nor the database contains the identity of the patient (surname, first name). The patient is identified in these 2 documents by a number. The match between names and identification numbers is kept in another file, kept separate from medical information; He ensures the follow-up of the patients participating in the study.

The database is centralized, backed up daily. All these operations are performed continuously, that is, as the data is collected.

Statistics :

Statistical analysis of the data will be performed using IBM SPSS statistical analysis software.

All data are expressed as a mean ± standard deviation, median, frequency or percentage, if applicable.

The materiality level (level α ) is set at 0.05.

Statistical analysis includes:

* A description of patients includes:

  1. Number of patients
  2. Age, sex, weight, height, BMI
  3. Pathologies
* A description of deviations from the protocol: number and % of patients incorrectly included, patients lost at follow-up, patients who did not use the telemedicine system
* A description of all data collected during V1 and V2, as well as during the 3-day collection period.

The frequency distributions will be analyzed with the Chi² test.

For NivolisMonitor:

The Anova analysis will be used to analyze all quantitative data collected during V1 and V2 and during the 3-day collection period.

Data collected from VNI software and NivolisMonitor will be analyzed with a single-factor Anova analysis. A linear regression analysis will be conducted, in addition, a visual analysis by the Bland and Altman method will be performed.

For NivolisAnton:

The comparison between the data collected by NivolisAnton and the Sentec SDM Transcutaneous Capnia Monitor will be performed using Anova Analysis (repeated measurements), one-factor regression analysis, and Bland and Altman visual evaluation.

For the evaluation of Usability/Acceptability, the data collected and the responses to the questionnaires will be expressed in frequency (percentage).

Eligibility criteria: Inclusion Criteria:

* Patients treated with home ventilatory devices: NIV (Philipps Dreamstation or Resmed Lumis) or HDN

  * COPD patient treated with NIV or HDN according to current recommendations
  * Patient with Obesity Hypoventilation Syndrome treated with NIV or HDN according to current recommendations

Exclusion Criteria:

* Progressive and life-threatening condition in the short term (1 year) (cancer, rapidly progressing neuromuscular disease) (at physician's discretion)
* Patients treated with NIV other than Philipps Dreamstation or Resmed Lumis
* Hospitalization leading to NIV discontinuation for at least 1 week during the screening phase
* Person deprived of liberty
* Adult protected by law
* Pregnant and breastfeeding women

Primary outcomes:
measure: Ventilatory frequency expressed in breaths.min-1
timeFrame: At the end of the 3-day monitoring period
measure: Leaks expressed in L.min-1
timeFrame: At the end of the 3-day monitoring period
measure: Use of the device expressed in Hours
timeFrame: At the end of the 3-day monitoring period
measure: Air Flow expressed in L.min-1
timeFrame: At the end of the 3-day monitoring period
measure: FiO2 expressed as percent
timeFrame: At the end of the 3-day monitoring period
measure: Temperature Expressed in degree Celsius
timeFrame: At the end of the 3-day monitoring period
measure: Relative Humidity expressed as percent RH
timeFrame: At the end of the 3-day monitoring period
measure: Device Use expressed in Hours
timeFrame: At the end of the 3-day monitoring period
measure: TcPCO2 values expressed in mm Hg
timeFrame: At the end of the 3-day monitoring period
Secondary outcomes:
measure: Patient Usability of NivolisMonitor
timeFrame: At the end of the 3-day monitoring period
measure: Health Practitioner Usability of NivolisMonitor
timeFrame: At the end of the 3-day monitoring period
measure: Health Practitioner Usability of NivolisAnton
timeFrame: At the end of the 3-day monitoring period
measure: tcPCO2 corrected values expressed in mm Hg
timeFrame: At the end of the 3-day monitoring period
measure: SaO2 expressed in %
timeFrame: At the end of the 3-day monitoring period
measure: Heart Rate (HR) in Beats Per Minute
timeFrame: At the end of the 3-day monitoring period
Other outcomes:
Locations:
city: Grenoble
country: France
facility: CHU Grenoble Alpes
Study officials:
affiliation: University Hospital, Grenoble
name: Jean-Louis Pépin, Professor
role: PRINCIPAL_INVESTIGATOR
References: